TrialJAMA oncology2019

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Lillian L Siu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.